NCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
Johns Hopkins University
Shengjing Hospital
Reveal Pharmaceuticals Inc.
Massachusetts General Hospital
SpringWorks Therapeutics, Inc.
Medical College of Wisconsin
University of Alabama at Birmingham